Gain Therapeutics, Inc. (GANX): Price and Financial Metrics


Gain Therapeutics, Inc. (GANX): $3.95

0.05 (+1.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GANX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GANX POWR Grades

  • Growth is the dimension where GANX ranks best; there it ranks ahead of 43.16% of US stocks.
  • GANX's strongest trending metric is Sentiment; it's been moving down over the last 42 days.
  • GANX ranks lowest in Momentum; there it ranks in the 6th percentile.

GANX Stock Summary

  • GANX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.47 -- higher than just 4.24% of US-listed equities with positive expected earnings growth.
  • GANX's went public 1.86 years ago, making it older than just 6.8% of listed US stocks we're tracking.
  • GANX's price/sales ratio is 275.5; that's higher than the P/S ratio of 98.63% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GAIN THERAPEUTICS INC are FKWL, ACER, DAIO, ALLT, and VTVT.
  • Visit GANX's SEC page to see the company's official filings. To visit the company's web site, go to www.gaintherapeutics.com.

GANX Valuation Summary

  • In comparison to the median Healthcare stock, GANX's price/earnings ratio is 112.33% lower, now standing at -2.8.
  • GANX's price/sales ratio has moved down 4127.8 over the prior 22 months.

Below are key valuation metrics over time for GANX.

Stock Date P/S P/B P/E EV/EBIT
GANX 2023-01-20 248.1 2.0 -2.8 -2.2
GANX 2023-01-19 240.4 1.9 -2.7 -2.1
GANX 2023-01-18 241.0 1.9 -2.7 -2.1
GANX 2023-01-17 244.3 2.0 -2.8 -2.2
GANX 2023-01-13 251.9 2.0 -2.9 -2.3
GANX 2023-01-12 245.9 2.0 -2.8 -2.2

GANX Price Target

For more insight on analysts targets of GANX, see our GANX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.00 Average Broker Recommendation 1 (Strong Buy)

GANX Stock Price Chart Interactive Chart >

Price chart for GANX

GANX Price/Volume Stats

Current price $3.95 52-week high $6.70
Prev. close $3.90 52-week low $2.33
Day low $3.91 Volume 30,509
Day high $4.05 Avg. volume 46,280
50-day MA $3.34 Dividend yield N/A
200-day MA $3.44 Market Cap 46.94M

Gain Therapeutics, Inc. (GANX) Company Bio


Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.


GANX Latest News Stream


Event/Time News Detail
Loading, please wait...

GANX Latest Social Stream


Loading social stream, please wait...

View Full GANX Social Stream

Latest GANX News From Around the Web

Below are the latest news stories about GAIN THERAPEUTICS INC that investors may wish to consider to help them evaluate GANX as an investment opportunity.

Sidoti's January Micro-Cap Conference

Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 18-19, 2023.

Yahoo | January 17, 2023

Gain Therapeutics to Present at Sidoti Small-Cap Virtual Investor Conference

BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced that Matthias Alder, CEO, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on Wednesday, January 18 at 2:30 PM ET. A webcast of the presentation

Yahoo | January 12, 2023

Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief Executive Officer and Appointed him to the Board of Directors $25.7 Million in Cash and Cash Equivalents and Marketable Securities as of September 30, 2022 Provides Strong Financial Foundation and Extends Cash Runway into Q2 2024 BETHESDA, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics,

Yahoo | November 10, 2022

Gain Therapeutics Touts Additional Encouraging Preclinical Data For Lead Parkinson's Program

Gain Therapeutics Inc (NASDAQ: GANX) announced the presentation of new preclinical data evaluating one of its lead Structurally Targeted Allosteric Regulator (STAR) compounds, GT-02287, for Parkinson's Disease. The study was conducted using human-induced pluripotent stem cells (iPSC) derived from donor patients with GBA-associated Parkinson's disease, which were then differentiated into dopaminergic neurons. GT-02287 demonstrated statistically significant, positive effects across a range of meas

Yahoo | September 26, 2022

Read More 'GANX' Stories Here

GANX Price Returns

1-mo 26.20%
3-mo 24.21%
6-mo -0.50%
1-year -1.25%
3-year N/A
5-year N/A
YTD 26.20%
2022 -42.36%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7591 seconds.